IsoRay, Inc. (NYSEMKT:ISR) received a $3.00 price objective from Maxim Group in a report issued on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Maxim Group’s price objective points to a potential upside of 383.87% from the stock’s current price.

IsoRay (ISR) traded up 0.81% during mid-day trading on Thursday, hitting $0.62. The stock had a trading volume of 71,944 shares. IsoRay has a 12 month low of $0.48 and a 12 month high of $0.89. The stock’s market cap is $34.11 million. The stock’s 50-day moving average price is $0.56 and its 200-day moving average price is $0.58.

IsoRay (NYSEMKT:ISR) last released its earnings results on Wednesday, May 10th. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter. IsoRay had a negative return on equity of 42.36% and a negative net margin of 106.08%. The business had revenue of $1.28 million for the quarter. On average, analysts predict that IsoRay will post ($0.09) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “IsoRay, Inc. (ISR) PT Set at $3.00 by Maxim Group” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at

About IsoRay

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Receive News & Ratings for IsoRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay Inc. and related companies with's FREE daily email newsletter.